Company Listing
Verona Pharma

Verona Pharma is developing a first-in-class therapeutic to treat respiratory diseases. The inhaled dual phosphodiesterase PDE3/PDE4 inhibitor with both bronchodilator and anti-inflammatory properties is in clinical trials for chronic obstructive pulmonary disease (COPD) and acute asthma. Verona Pharma is a VIPE (Venture Investment in Public Equity) and is listed on AIM.

 

BACK
Location
London, UK
CEO
Jan-Anders Karlsson
Abingworth Partner
Andrew Sinclair
Website Address

Home

About Us

  1. About Us
  2. Our Team
  3. Transatlantic Reach
  4. Funds

Strategy

  1. Our Strategy
  2. Venture Capital
  3. Clinical Co‑development
  4. VIPEs
  5. Public Markets

Portfolio

  1. Portfolio Companies
  2. Case Studies

Media Centre

  1. Recent News
  2. Archived News
  3. Film

Contact

  1. Contact Us
  2. Send Us Your Proposal
Company Listing

Verona Pharma is developing a first-in-class therapeutic to treat respiratory diseases. The inhaled dual phosphodiesterase PDE3/PDE4 inhibitor with both bronchodilator and anti-inflammatory properties is in clinical trials for chronic obstructive pulmonary disease (COPD) and acute asthma. Verona Pharma is a VIPE (Venture Investment in Public Equity) and is listed on AIM.

 

Location
London, UK
CEO
Jan-Anders Karlsson
Abingworth Partner
Andrew Sinclair
Website Address
BACK
 
Copyright Abingworth 2017